Glaukos Corp
(NY:
GKOS
)
129.28
+0.93 (+0.72%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Glaukos Corp
< Previous
1
2
3
4
5
Next >
Navigating 11 Analyst Ratings For Glaukos
August 28, 2024
Via
Benzinga
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
August 01, 2024
Via
Benzinga
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
August 01, 2024
Via
Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
7 Leading MedTech Stocks for Next-Gen Health Solutions
July 31, 2024
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.
Via
InvestorPlace
10 Analysts Have This To Say About Glaukos
July 10, 2024
Via
Benzinga
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
May 22, 2024
Via
Benzinga
Analyst Ratings For Glaukos
April 08, 2024
Via
Benzinga
5 Analysts Have This To Say About Glaukos
March 22, 2024
Via
Benzinga
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
July 10, 2024
Via
Benzinga
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
May 02, 2024
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.
Via
Benzinga
Topics
Earnings
Exposures
Financial
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
May 02, 2024
Via
Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
May 01, 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Glaukos: Q4 Earnings Insights
February 21, 2024
Via
Benzinga
Earnings Scheduled For February 21, 2024
February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via
Benzinga
Analyst Ratings For Glaukos
February 16, 2024
Via
Benzinga
Unveiling 7 Analyst Insights On Glaukos
December 21, 2023
Via
Benzinga
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
April 03, 2024
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
February 22, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
December 21, 2023
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Analyst Ratings for Glaukos
November 28, 2023
Via
Benzinga
4 Analysts Have This to Say About Glaukos
November 08, 2023
Via
Benzinga
8 Analysts Have This to Say About Glaukos
September 26, 2023
Via
Benzinga
iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
December 15, 2023
Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog...
Via
Benzinga
Exposures
Product Safety
Dow Extends Rally As Treasury Yields Tank
December 14, 2023
The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision.
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
December 14, 2023
The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for...
Via
Benzinga
Exposures
Product Safety
Glaukos's Earnings Outlook
August 01, 2023
Via
Benzinga
Analyst Ratings for Glaukos
July 31, 2023
Via
Benzinga
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
July 19, 2023
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.